photonamic GmbH &

Company snapshot

As a wholly-owned subsidiary of the Japanese SBI Group, photonamic GmbH Co. KG explores and develops various applications for the lead compound 5-aminolevulinic acid (5-ALA). Our development is focused on innovative applications of 5-ALA in the medical field, as well as in cosmetics and food supplements.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for photonamic GmbH &. Not investment advice.

• What is photonamic GmbH &?

  Photonamic GmbH & is a pharma organization headquartered in EU. Primary therapeutic focus areas include Colorectal Carcinoma, Glioblastoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.go

• Is photonamic GmbH & publicly traded?

  photonamic GmbH & appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does photonamic GmbH & develop or market?

  We link 3 drug profile(s) where photonamic GmbH & is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/photonamic-gmbh-co-kg#company-drugs.

• What are the latest developments for photonamic GmbH &?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does photonamic GmbH & focus on?

  photonamic GmbH & focuses on Colorectal Carcinoma, Glioblastoma based on our analysis of their pipeline programs and drug development activities.